01—Abstract
Summary
Summary of the 10-K filed March 1, 2007. Cited figures are marked; the original filing is the authoritative source.
IDEXX Laboratories' 2006 Form 10-K shows a company that grew revenue 16% to $739.1 milliona and net income 20% to $93.7 million (diluted EPS $2.84, up from $2.30).
Growth was driven mainly by the Companion Animal Group (CAG), which rose 16% to $606.3 millionb on higher instrument and consumables volume, reference laboratory acquisitions, and strong practice-level demand for SNAP 4Dx and VetTest slides. Gross margin held roughly flat at 51.3%. Operating margin fell to 17.3% from 18.1%, largely because adopting SFAS 123(R) added about $9.0 million of share-based compensation to operating expenses, and an unallocated corporate cost line rose sharply.
The 28.4% effective tax rate, down from 34.2%, was helped by a $3.7c-point benefit from resolving an IRS audit, so the earnings jump is partly flattered by one-time items. The balance sheet and cash flow picture is more mixed. Operating cash flow fell to $109.8 million from $116.6 million, partly because $9.4 million of tax benefits moved to financing cash flows and inventories rose $25.7 million.
Cash and short-term investments declined to $96.7 million, and inventories increased to $96.0 milliond. Management used cash for buybacks ($105.7 million of stock repurchased in 2006) and acquisitions. Subsequent to year-end, IDEXX bought the Critical Care Division of Osmetech plc for about $45 million, entering the human point-of-care electrolyte and blood gas market, and it agreed to acquire Institut Pourquier.
It also arranged a $125 million short-term credit facility, which it expected to replace with a longer-term facility before June 2007. Management plans a major product transition, with Catalyst Dx and SNAPshot Dx both targeted for January 2008. Key risks for investors include concentration in U.S. distributors (Butler Animal Health Supply was 9% of 2006 revenue), roughly $169 million of purchase obligations, dependence on single-source suppliers including Ortho for VetTest slides, a near-term revenue threat from the U.K.
Cryptosporidium testing rule change (about $2.9 million of Filta-Max sales), and the eventual loss of an FDA-discretion pharmaceutical product (about $11.9 million of 2006 revenue). The company has never paid a cash dividend, and it reported no material legal proceedings.
02—Key points
Key Highlights
- Revenue rose 15.8% to $739.1 million in 2006, with CAG contributing $606.3 million (+16%), led by reference laboratory services (+19.6%) and instruments and consumables (+11.4%).
- Diluted EPS increased 23% to $2.84 (net income +20% to $93.7 million), though the 28.4% tax rate benefited from a one-time IRS audit resolution worth 3.7 points.
- Operating margin declined to 17.3% from 18.1% as share-based compensation under SFAS 123(R) added $9.0 million to operating expenses and unallocated corporate costs rose to $14.9 million.
- Operating cash flow decreased to $109.8 million from $116.6 million, partly due to a $9.4 million reclassification of tax benefits to financing and a $25.7 million increase in inventories.
- Aggressive capital return: $105.7 million of share repurchases in 2006, plus a February 2007 board increase of 2 million shares to the buyback authorization.
- Expansion into human point-of-care diagnostics via the ~$45 million Osmetech Critical Care Division acquisition (January 2007), alongside the pending Institut Pourquier acquisition (~$7.5 million in sales).
- Product pipeline catalysts: Catalyst Dx (chemistry) and SNAPshot Dx (immunoassay) both targeted for January 2008, with significant contract and supply dependencies on Ortho and others.
03—Questions
Frequently Asked Questions
How much of IDEXX's 2006 growth was organic versus acquired?
Total revenue grew 15.8%, of which about 1.8 points came from acquisitions, 0.4 points from currency, and about 13.6 points from underlying growth net of those effects. Acquisitions were concentrated in CAG, mainly veterinary reference laboratories, a digital radiography business, and rapid assay distribution rights.
Why did operating margin decline even though gross margin was stable?
Gross margin was roughly flat at 51.3% versus 50.6%. Operating expenses rose to 34.0% of revenue from 32.5%, mainly because SFAS 123(R) share-based compensation added about $9.0 million of expense, and unallocated corporate R&D and G&A grew. Lower-margin reference laboratory revenue and newly acquired labs also weighed on profitability.
What are the main concentration and supplier risks?
U.S. distributors are the company's largest customers, and Butler Animal Health Supply alone accounted for 9% of 2006 revenue. Key suppliers are single-source: Ortho supplies all VetTest slides under agreements running through 2020, with minimum purchases of $59.0 million through 2010, and QBCD and Roche supply other analyzers. Distributor purchasing patterns can also distort reported sales versus end-user demand.
What near-term revenue risks should investors watch?
The U.K. Drinking Water Inspectorate proposed ending mandatory Cryptosporidium testing effective December 2007, which could eliminate most of the $2.9 million of Filta-Max sales in England and Wales. Separately, a veterinary pharmaceutical product generating $11.9 million in 2006 could be forced off the market if the FDA approves a competing product, though inventory is adequate until late 2008 or early 2009.
How is the company funding acquisitions and buybacks, and is liquidity adequate?
Cash and short-term investments fell to $96.7 million, and working capital to $177.5 million. In January 2007 the company obtained a $125 million unsecured revolving facility maturing June 30, 2007, which it expects to replace with a longer-term facility. Total debt was $7.1 million at year-end, mostly a mortgage on the Westbrook, Maine headquarters. Management believes existing resources and credit availability are sufficient for operations and planned growth, including a 2007 capital plan of roughly $65 million.
04—Continue